2020 will go down as one of the most difficult for companies and leaders around the world. The corona virus has taken lives, isolated families, closed airports and put a fear into many like never before. Whilst most of us have had the privilege of a stable life occupied with routine, the future is now …
Optalert’s sophisticated software algorithm, leads the drowsiness monitoring field, by providing the next level layer within driver monitoring systems (DMS). Optalert’s scientifically validated Johns Drowsiness Scale (JDSTM) enables an objective, real time, quantifiable measure of drowsiness. Applicable across ethnicity, gender and age, the JDS™ empowers the driver with the ability to avoid dangerous microsleeps. Providing …
What is the Optalert JDS™ and why is it leading the drowsiness monitoring field? Read More »
September is World Alzheimer’s month, the international campaign which raises awareness and challenges the stigma that surrounds dementia. Around the world 50 million people have dementia, and each year there are nearly 10 million new cases. The total number of people with dementia is projected to reach 82 million by 2030! With over 100 forms …
Could blinks be the answer to Alzheimer’s disease? Read More »
BIO International Convention is back in Philadelphia, June 3-6, to celebrate the globally important innovations in biotech that start with one: one meeting, one theory, one trial, one breakthrough. Optalert look forward to joining the global biotech community during partnering sessions and will be available for meetings through the official Bio2019 partnering portal, opening …
The Consumer Electronics Show (CES2019) dazzled participants once again with glimpses of technologies and products on the horizon for the future. With over 180,000 attendees from 150 different countries, circulating over 11 venues throughout Las Vegas. Optalert’s key conversations at this year’s event included autonomous vehicles, enhanced ‘early warning’ drowsiness and distraction features, and AI …
Optalert is pleased to introduce the BlinQ system for the measurement of drowsiness or wakefulness in clinical trials. Optalert uses advanced patented algorithms to determine the exact drowsiness or wakefulness of a subject. By applying Artificial Intelligence techniques and machine learning Optalert has been able to objectively quantify drowsiness or wakefulness. Utilising the Johns Drowsiness Scale (JDS), Optalert’s future-proofed …
Pharmaceutical companies face many challenges, with hundreds of new drugs required to transition through clinical trial phases, regulatory processes and to market, more quickly and more efficiently. The Centre for the Study of Drug Development (CSDD) estimates the cost of developing a prescription drug that gains market approval at $2.6 billion. Even more remarkable is …
Every technological discovery aims to improve our health, safety, and quality of life. Every day, we marvel over exciting new developments that emerge from each corner of the globe. A few weeks ago, we looked at seven of the most significant pharmacological discoveries, and this week, we want to expand our exploration into great technology …
5 of the greatest technological discoveries in the medical field Read More »
Optalert revolutionises pharmaceutical research with in-clinic test for wakefulness. Richmond, VIC: Optalert is pleased to introduce its latest wakefulness detection technology to the pharmaceutical industry for use during clinical drug trials. Optalert’s technology enhances clinical testing by offering pharmaceutical researchers an objective, measurable and real-time scale of drowsiness in addition to the alternative wakefulness, common …
It is estimated global pharmaceutical company Johnson and Johnson employs more than 127,000 people. And in the US alone more than 800,000 people work in the pharmaceutical industry developing, testing, and producing drugs for a range of medical ailments. From vaccinations and Insulin to contraception, each medication must face scrutiny and assessment through vigilant testing …
ABOUT US
CONTACT US
© Optalert. All Rights Reserved. Digital Agency
